Financials data is unavailable for this security.
View more
Year on year Hunan Fangsheng Pharmaceutical Co Ltd 's revenues fell -9.12% from 1.79bn to 1.63bn. has fallen -34.64% from 285.85m to 186.82m.
Gross margin | 68.22% |
---|---|
Net profit margin | 12.43% |
Operating margin | 13.62% |
Return on assets | 6.67% |
---|---|
Return on equity | 14.92% |
Return on investment | 11.80% |
More ▼
Cash flow in CNYView more
In 2023, cash reserves at Hunan Fangsheng Pharmaceutical Co Ltd fell by 201.41m. However, the company earned 87.54m from its operations for a Cash Flow Margin of 5.38%. In addition the company used 197.40m on investing activities and also paid 91.55m in financing cash flows.
Cash flow per share | -- |
---|---|
Price/Cash flow per share | -- |
Book value per share | 3.44 |
---|---|
Tangible book value per share | 2.23 |
More ▼
Balance sheet in CNYView more
Current ratio | 0.7422 |
---|---|
Quick ratio | 0.472 |
Total debt/total equity | 0.5688 |
---|---|
Total debt/total capital | 0.3458 |
More ▼
Growth rates in CNY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth dropped -17.14% and -36.90%, respectively. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
Div yield(5 year avg) | 2.39% |
---|---|
Div growth rate (5 year) | 4.75% |
Payout ratio (TTM) | 40.54% |
EPS growth(5 years) | 19.21 |
---|---|
EPS (TTM) vs TTM 1 year ago | -33.92 |
More ▼